fluoxtca: Cost-Effectiveness data for 1242 MDD patients from...

In ICEinfer: Incremental Cost-Effectiveness Inference using Two Unbiased Samples

Description

In 1990-1992, the Marketscan(SM) database included medical and pharmacy claims for approximately 700,000 individuals whose health insurance was provided by large corporations throughout the United States. Outcomes for 1242 patients treated with either fluoxetine (SSRI) or with a TCA / HCA for major depressive disorder (MDD) were discussed in Croghan et al. (1996) and Obenchain et al. (1997). All 1242 patients were continuously enrolled for at least 4 months prior to their initial antidepressant prescription and for the following 12 months.

Usage

data(fluoxtca)

Format

A data frame of 3 variables on 1242 patients; no NAs.

stable

stable = 1 indicates that the patient remained on his/her initial antidepressant medication for at least six consecutive months.

cost

cost is the Marketscan(SM) 12 month total annual charge for a patient.

fluox

Treatment indicator variable; fluox = 1 indicates receipt of fluoxetine 20 mg/d by 799 patients. fluox = 0 implies receipt of either a tricyclic (TCA) or a heterocyclic (HCA) by 443 patients.

Details

This dataset contains measures of cost and efffectiveness for 799 patients treated with fluoxetine (a Selective Serotonin Reuptake Inhibitor or SSRI), 104 patients treated with a first generation tricyclic, TCA (amitriptyline or imipramine), 250 patients treated with a second generation TCA (desipramine or nortriptyline), and 89 patients treated with trazodone (a heterocyclic, HCA).

References

Croghan TW, Lair TJ, Engelhart L, et al. Effect of antidepressant therapy on health care utilization and costs in primary care. Working paper, Eli Lilly and Company, 1996. (Presented in part at the Association for Health Services Research meeting, Chicago, June 9, 1995.)

Obenchain RL, Melfi CA, Croghan TW, Buesching DP. Bootstrap analyses of cost-effectiveness in antidepressant pharmacotherapy. PharmacoEconomics 1997; 17: 1200–1206.

Sclar DA, Robison LM, Skaer TL, Legg RF, Nemec NL, Galin RS, Hugher TE, Buesching DP. Antidepressant pharmacotherapy: economic outcomes in a health maintenance organization. Clin Ther 1994; 16: 715–730.

Examples

  data(fluoxtca)
  ICEscale(fluoxtca, fluox, stable, cost)

Example output

Loading required package: lattice

Incremental Cost-Effectiveness (ICE) Lambda Scaling Statistics

Specified Value of Lambda   = 1
Cost and Effe Differences are both expressed in cost units

Effectiveness variable Name = stable
     Cost     variable Name = cost
  Treatment   factor   Name = fluox
New treatment level is = 1 and Standard level is = 0 

Observed  Treatment Diff = 0.117
Std. Error of Trtm Diff  = 0.028 

Observed Cost Difference = -192.935
Std. Error of Cost Diff  = 1003.158 

Observed  ICE  Ratio     = -1647.861 

Statistical Shadow Price = 36416.684
Power-of-Ten Shadow Price= 10000 

ICEinfer documentation built on Oct. 23, 2020, 8:31 p.m.